AUTHOR=Yuan Ge , Liu Xiangliang , Zhang Xinwei , Song Wei , Lu Jin , Ding Zhongyang , Chen Xiao 

TITLE=Remarkable response to PD-1 inhibitor in a patient with extensive-stage small cell lung cancer: a case report and literature review

JOURNAL=Frontiers in Immunology

VOLUME=14

YEAR=2023

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1267606

DOI=10.3389/fimmu.2023.1267606

ISSN=1664-3224

ABSTRACT=<p>We report a case of a 59-year-old male diagnosed with extensive-stage small cell lung cancer (SCLC). He received first-line platinum doublet chemotherapy and second-line topotecan-based regimen, but experienced disease progression after each line of therapy. He was then treated with Sintilimab, a PD-1 inhibitor, in combination with nab-paclitaxel in the third-line setting, which resulted in significant tumor shrinkage. Restaging scans showed a partial response per RECIST criteria with 62% reduction in tumor burden. This case highlights the application and efficacy of immune checkpoint inhibitors in extensive-stage SCLC.</p>